There is activation of the renin-angiotensin-aldosterone system (RAAS) in the pathophysiological process of many kinds of cardiovascular and renal diseases. So, angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) become the first-line drugs for current antihypertensive therapies in medical practices. For a long period, rennin has been considered as the most classical and logical drug target. Aliskiren, however, as the first renin inhibitor, not until 2007, has been allowed for the treatment of hypertension. Nowadays, aliskiren attracts more and more attention because of its well-control in hypertension and greater protection from hypertensive complications. Since aliskiren has better effect on more complete RAAS inhibition, great achievements were made when it is used in combination therapy for its contribution to well-controlled baseline blood pressure and several cardioprotective and renoprotective effects. In this article, we reviewed extensively the progress of clinical application of aliskiren in recent years.% 许多心血管疾病和肾脏疾病的病理生理过程都伴有肾素-血管紧张素-醛固酮系统（RAAS）的激活。在高血压的治疗方案中，血管紧张素转化酶抑制剂（ACEIs）和血管紧张素受体阻滞剂（ARBs）成为一线用药。长期以来肾素被认为是RAAS中最经典、最合乎逻辑的药物靶标，然而，首个肾素抑制剂阿利吉仑在2007年才被批准用于高血压疾病的治疗。近年来阿利吉仑良好的血压控制效果及脏器保护效应备受关注。因阿利吉仑能更完全地抑制RAAS，以其为基础的联合用药方案对于预防高血压并发症业已取得良好效果。本文就近年来阿利吉仑在临床应用中的研究进展进行综述。
展开▼
